Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | AOC1 | P19801 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24827531 | 0.86 | ALDH1A1 (0.41) | SLC6A2SLC6A4ALDH1A1HCAR3AOC3 | |
| SCHEMBL5716104 | 0.81 | NR3C2 (0.39) | ALDH1A1HCAR3POLBAPEX1TDP1 | |
| SCHEMBL2850957 | 0.81 | SLC6A2 (0.35) | SLC6A2SLC6A4ALDH1A1SLC6A3 | |
| SCHEMBL19908622 | 0.79 | HCAR3 (0.39) | SLC6A2SLC6A4ALDH1A1HCAR3GAA | |
| SCHEMBL2840431 | 0.77 | SLC6A2 (0.36) | SLC6A2SLC6A4ALDH1A1AOC3GAA | |
| SCHEMBL28076318 | 0.77 | GAA (0.55) | SLC6A2SLC6A4ALDH1A1GAAKMT2A | |
| SCHEMBL11969279 | 0.75 | HCAR3 (0.36) | ALDH1A1HCAR3GAAKMT2APOLB | |
| SCHEMBL21636847 | 0.75 | MAPT (0.44) | SLC6A2SLC6A4ALDH1A1AOC3KMT2A | |
| SCHEMBL8313735 | 0.74 | HRH4 (0.41) | SLC6A2SLC6A4ALDH1A1AOC3GAA | |
| SCHEMBL19848298 | 0.74 | ALDH1A1 (0.39) | SLC6A2SLC6A4ALDH1A1AOC3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304461-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-10-20 | — | — | US | disclosed |
| US-9403773-B2 | Quinolone compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-02 | — | — | US | disclosed |
| US-20150218101-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-08-06 | — | — | US | disclosed |
| US-9045464-B2 | Quinolone compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-06-02 | — | — | US | disclosed |
| US-20140121207-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-05-01 | — | — | US | disclosed |
| US-8642619-B2 | Quinolone compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-02-04 | — | — | US | disclosed |
| US-20120316168-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-12-13 | — | — | US | disclosed |
| US-8269011-B2 | Quinolone compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20100130546-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-0897921-A1 | Benzothiadiazinyl-indole derivatives and their use as serotonin receptor ligands | ELI LILLY AND COMPANY LIMITED (GB) | 1999-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316168-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | PARK7, SNCA, LRRK2 | SLC6A2 103/4885SLC6A4 212/4885ALDH1A1 692/4885 |
| US-20140121207-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | PARK7, SNCA, LRRK2 | SLC6A2 103/4885SLC6A4 212/4885ALDH1A1 692/4885 |
| US-20160304461-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | PARK7, SNCA, LRRK2 | SLC6A2 103/4885SLC6A4 212/4885ALDH1A1 692/4885 |
| US-20100130546-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | PARK7, SNCA, LRRK2 | SLC6A2 103/4885SLC6A4 212/4885ALDH1A1 692/4885 |
| US-20150218101-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | PARK7, SNCA, LRRK2 | SLC6A2 103/4885SLC6A4 212/4885ALDH1A1 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.